96 related articles for article (PubMed ID: 16050006)
1. JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Luckman SP; Hughes DE; Coxon FP; Russell GG; Rogers MJ
J Bone Miner Res; 2005 Jul; 20(7):1265-74. PubMed ID: 16050006
[No Abstract] [Full Text] [Related]
2. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Luckman SP; Hughes DE; Coxon FP; Graham R; Russell G; Rogers MJ
J Bone Miner Res; 1998 Apr; 13(4):581-9. PubMed ID: 9556058
[TBL] [Abstract][Full Text] [Related]
3. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells.
Oades GM; Senaratne SG; Clarke IA; Kirby RS; Colston KW
J Urol; 2003 Jul; 170(1):246-52. PubMed ID: 12796698
[TBL] [Abstract][Full Text] [Related]
4. [The role of mevalonate pathway in osteogenic cells].
Ishimi Y
Nihon Rinsho; 2004 Feb; 62 Suppl 2():779-82. PubMed ID: 15035226
[No Abstract] [Full Text] [Related]
5. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
[TBL] [Abstract][Full Text] [Related]
6. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Rogers MJ
Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
[TBL] [Abstract][Full Text] [Related]
7. Protein prenylation: key to ras function and cancer intervention?
Khosravi-Far R; Cox AD; Kato K; Der CJ
Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908
[No Abstract] [Full Text] [Related]
8. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Dunford JE; Rogers MJ; Ebetino FH; Phipps RJ; Coxon FP
J Bone Miner Res; 2006 May; 21(5):684-94. PubMed ID: 16734383
[TBL] [Abstract][Full Text] [Related]
10. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
[TBL] [Abstract][Full Text] [Related]
11. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
12. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
van beek E; Löwik C; van der Pluijm G; Papapoulos S
J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
[TBL] [Abstract][Full Text] [Related]
13. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts.
Woo JT; Kasai S; Stern PH; Nagai K
J Bone Miner Res; 2000 Apr; 15(4):650-62. PubMed ID: 10780857
[TBL] [Abstract][Full Text] [Related]
14. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE; Rogers MJ; Halasy JM; Luckman SP; Hughes DE; Masarachia PJ; Wesolowski G; Russell RG; Rodan GA; Reszka AA
Proc Natl Acad Sci U S A; 1999 Jan; 96(1):133-8. PubMed ID: 9874784
[TBL] [Abstract][Full Text] [Related]
15. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
[TBL] [Abstract][Full Text] [Related]
16. Regulation of proliferation and Ras localization in transformed cells by products of mevalonate metabolism.
Cuthbert JA; Lipsky PE
Cancer Res; 1997 Aug; 57(16):3498-505. PubMed ID: 9270019
[TBL] [Abstract][Full Text] [Related]
17. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Staal A; Frith JC; French MH; Swartz J; Güngör T; Harrity TW; Tamasi J; Rogers MJ; Feyen JH
J Bone Miner Res; 2003 Jan; 18(1):88-96. PubMed ID: 12510809
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells.
Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS
Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631
[TBL] [Abstract][Full Text] [Related]
19. Nitrogen-containing bisphosphonate mechanism of action.
Reszka AA; Rodan GA
Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
[TBL] [Abstract][Full Text] [Related]
20. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Shipman CM; Croucher PI; Russell RG; Helfrich MH; Rogers MJ
Cancer Res; 1998 Dec; 58(23):5294-7. PubMed ID: 9850051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
